Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
<ul type="disc"> <li>Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME</li> <li>Objective response rate (ORR): 64% (7/11) initial ORR at week 6 and 67% (6/9) confirmed Mehr



